CMS granted coverage for Personalis’ NeXT Personal MRD assay to monitor stages I–III non‑small cell lung cancer in the surveillance setting, the company announced. The decision follows clinical validation in the TRACERx consortium and evidence published in Nature Medicine that supported the test’s sensitivity for detecting residual disease via whole‑genome sequencing and advanced noise suppression. Personalis said coverage broadens patient access and will accelerate commercialization; the company has partnered with Tempus AI to scale the test across breast, lung and colorectal cancer surveillance programs. Medicare decisions can materially affect clinical uptake and reimbursement pathways for tumor‑informed MRD assays.